PCV13 Immunization Recommendations for Healthy Infants
Recommended Primary and Booster Schedule
- The CDC recommends that healthy infants receive the 13‑valent pneumococcal conjugate vaccine (PCV13) in a 4‑dose series at ages 2 months, 4 months, 6 months, and a booster at 12–15 months; the booster must be given at least 8 weeks after the third dose. 1
- For infants who begin vaccination between 2 months and 6 months of age, three primary doses are administered at 2, 4, and 6 months, with a minimum interval of 4 weeks between each primary dose. 2
Catch‑Up Schedules for Delayed Initiation
- Infants 7–11 months (previously unvaccinated): give 2 primary doses spaced at least 4 weeks apart, followed by a booster at 12–15 months (≥8 weeks after the second dose). 3
- Children 12–23 months (previously unvaccinated): administer 2 doses with a minimum interval of 8 weeks; no booster is required. 4
- Children 24–59 months (previously unvaccinated): a single dose of PCV13 is sufficient. 4
Rationale for Using PCV13
- PCV13 replaced the earlier PCV7 formulation in 2010 and is now the standard of care for infant pneumococcal vaccination. 5
- The vaccine includes the 7 serotypes present in PCV7 (4, 6B, 9V, 14, 18C, 19F, 23F) plus six additional serotypes (1, 3, 5, 6A, 7F, 19A), broadening protection against invasive pneumococcal disease. 6
Efficacy Outcomes
- Clinical trials demonstrated 97.4 % efficacy against vaccine‑type invasive pneumococcal disease (IPD). 5
- Pooled analyses show 80 % efficacy against vaccine‑type IPD and 58 % efficacy against all‑serotype IPD. 6
- PCV13 reduces radiographically confirmed pneumonia by 27 % and clinical pneumonia by 6 %. 5
Safety Profile
- The safety profile of PCV13 is comparable to PCV7, with no major safety concerns identified. 1
- Common adverse events (reported in clinical studies) include:
- Injection‑site reactions – pain/tenderness (~48 %), erythema (~47 %), swelling (~35 %).
- Systemic symptoms – irritability (~70 %), drowsiness (~59 %), fever (~37 %).
- High‑grade fever (>39 °C) occurs in about 5 % of recipients. 2
Co‑Administration with Other Vaccines
- PCV13 may be given simultaneously with routine childhood vaccines provided each is administered in a separate syringe and injection site; co‑administration does not compromise immune responses to the other vaccines. 7
Special Considerations for Premature Infants
- Apnea has been observed following intramuscular vaccination in some premature infants; timing decisions should be individualized, weighing the infant’s medical status against the benefits of immunization. 3
Contraindications
- Severe allergic reaction to any component of PCV13, PCV7, or any diphtheria‑toxoid‑containing vaccine constitutes a contraindication. 8
Common Pitfalls to Avoid
- PPSV23 (23‑valent polysaccharide vaccine) should not be used in healthy infants; it is reserved for children ≥2 years with specific high‑risk conditions. 3
- If the vaccination series is interrupted, do not restart the series; continue with the age‑appropriate catch‑up schedule.
- Respect minimum intervals: 4 weeks between primary series doses for infants <12 months, and 8 weeks for all other dosing situations. 3
Pneumococcal Conjugate Vaccine Administration Guidelines
Introduction to PCV13 Administration
- The Centers for Disease Control and Prevention recommends a 4-dose series of PREVENAR 13 at 2, 4, 6, and 12-15 months of age for infants, while adults aged ≥65 years should receive one dose based on shared clinical decision-making unless they have specific risk factors 9, 10
Infant and Child Administration Schedule
- For infants starting at 2 months, a 4-dose series is recommended at ages 2, 4, 6, and 12-15 months, with a minimum interval of 4 weeks between doses for the primary series 9
- Children starting vaccination at 7-11 months should receive 3 doses: 2 doses at least 4 weeks apart, followed by a third dose at 12-15 months (at least 8 weeks after the second dose) 9
- Children starting vaccination at 12-23 months should receive 2 doses with an interval of at least 8 weeks between doses 9
- Children starting vaccination at 24-59 months who are healthy should receive 1 dose for previously unvaccinated or with incomplete schedule 9
- Children 24-71 months with underlying medical conditions should receive 2 doses for unvaccinated or with incomplete schedule of <3 doses (with at least 8 weeks between doses) 9
High-Risk Conditions in Children
- A single dose of PCV13 is recommended for children who have not received PCV13 previously and have anatomic or functional asplenia, immunocompromising conditions, cochlear implant, or cerebrospinal fluid leaks 11
Adult Administration Schedule
- PCV13 is no longer routinely recommended for all adults aged ≥65 years, instead, shared clinical decision-making is recommended for PCV13 use in adults ≥65 years who do not have immunocompromising conditions, CSF leaks, or cochlear implants 10
- Adults with immunocompromising conditions, cochlear implants, or CSF leaks should receive 1 dose of PCV13 if no previous PCV13 vaccination, followed by PPSV23 at least 8 weeks after PCV13 10
Important Administration Considerations
- When elective splenectomy, immunocompromising therapy, or cochlear implant placement is planned, complete PCV13 vaccination at least 2 weeks before the procedure or therapy 11
- For children who previously received PCV7, a supplemental dose of PCV13 is recommended to provide protection against additional serotypes 12
- The minimum interval between any PCV13 doses is 8 weeks 9